• What is NewCo?
    NewCo is an innovative model where Unibest identifies high-potential drug pipelines from Chinese pharmaceutical companies and facilitates their development and commercialization through an offshore entity. This approach combines our expertise in pharmaceutical assessment with strategic global partnership.
  • Pipeline Scouting
  • Investor Matchmaking
  • Due Diligence
  • Licensing Facilitation
  • Development Support
The pipeline

Currently in NewCo

The current pipeline features a diverse range of assets, including antibody drugs, small molecules, and ADCs targeting various cancers and autoimmune diseases from preclinical to Phase II.


We have also selected few commercial stage products markets in China open for licensing.

Download Assets
meeting

Interested for Licensing

Interested in one of our innovative pipelines? Let's discuss your licensing opportunities in depth. Schedule a meeting with Unibest experts to explore how we can collaborate on bringing cutting-edge pharmaceuticals to global markets.

Reserve A Meeting